TY - JOUR
T1 - ERS International Congress 2021
T2 - highlights from the Pulmonary Vascular Diseases Assembly
AU - Lichtblau, Mona
AU - Piccari, Lucilla
AU - Ramjug, Sheila
AU - Bokan, Aleksandar
AU - Lechartier, Benoit
AU - Jutant, Etienne-Marie
AU - Barata, Margarida
AU - Garcia, Agustin Roberto
AU - Howard, Luke S.
AU - Adir, Yochai
AU - Delcroix, Marion
AU - Jara-Palomares, Luis
AU - Bertoletti, Laurent
AU - Sitbon, Olivier
AU - Ulrich, Silvia
AU - Noordegraaf, Anton Vonk
N1 - Funding Information: Conflict of interest: M. Lichtblau has nothing to disclose. L. Piccari reports grants, personal fees and nonfinancial support from Janssen, and nonfinancial support from Menarini, outside the submitted work. S. Ramjug has nothing to disclose. A. Bokan has nothing to disclose. B. Lechartier has nothing to disclose. E-M. Jutant has nothing to disclose. M. Barata has nothing to disclose. A.R. Garcia has nothing to disclose. L.S. Howard reports grants and personal fees from Janssen, personal fees from MSD, GSK, Bayer, Third Pole, Gossamer Bio, Endotronix and United Therapeutics, outside the submitted work. Y. Adir reports personal fees from Teva, grants and personal fees from GSK and AstraZeneca, personal fees from Sanofi, grants and personal fees from Yansen, and personal fees from BI and Acceleron, outside the submitted work. M. Delcroix has nothing to disclose. L. Jara-Palomares has nothing to disclose. L. Bertoletti reports personal fees from Sanofi, personal fees and nonfinancial support from Leo-Pharma and Aspen, personal fees from Bayer, personal fees and nonfinancial support from BMS/Pfizer, and grants, personal fees and nonfinancial support from MSD, during the conduct of the study. O. Sitbon reports grants and personal fees from Acceleron Pharmaceuticals, personal fees from AOP Orphan, grants, personal fees and nonfinancial support from Bayer, personal fees from Ferrer and Gossamer Bio, grants from GlaxoSmithKline, and grants, personal fees and nonfinancial support from Janssen and MSD, outside the submitted work. S. Ulrich reports grants from Johnson and Johnson SA, the Swiss National Science Foundation, Zurich Lung and Orpha Swiss, and personal fees from MSD Switzerland and SA, outside the submitted work. A. Vonk Noordegraaf is supported by the Netherlands CardioVascular Research Initiative (CVON-2012-08 PHAEDRA and CVON-2017-10 DOLPHIN-GENESIS) and the Netherlands Organization for Scientific Research (NWO-VICI: 918.16.610). In addition, his institute has received speaker’s money from Johnson & Johnson, MSD, Actelion, Bayer and Ferrer in the past 3 years. Finally, he served as a member of the scientific advisory boards of Morphogen-X, Ferrer and Johnson & Johnson. Publisher Copyright: © The authors 2022.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - This article aims to summarise the latest research presented at the virtual 2021 European Respiratory Society (ERS) International Congress in the field of pulmonary vascular disease. In light of the current guidelines and proceedings, knowledge gaps are addressed and the newest findings of the various forms of pulmonary hypertension as well as key points on pulmonary embolism are discussed. Despite the comprehensive coverage of the guidelines for pulmonary embolism at previous conferences, discussions about controversies in the diagnosis and treatment of this condition in specific cases were debated and are addressed in the first section of this article. We then report on an interesting pro–con debate about the current classification of pulmonary hypertension. We further report on presentations on Group 3 pulmonary hypertension, with research exploring pathogenesis, phenotyping, diagnosis and treatment; important contributions on the diagnosis of post-capillary pulmonary hypertension are also included. Finally, we summarise the latest evidence presented on pulmonary vascular disease and COVID-19 and a statement on the new imaging guidelines for pulmonary vascular disease from the Fleischner Society.
AB - This article aims to summarise the latest research presented at the virtual 2021 European Respiratory Society (ERS) International Congress in the field of pulmonary vascular disease. In light of the current guidelines and proceedings, knowledge gaps are addressed and the newest findings of the various forms of pulmonary hypertension as well as key points on pulmonary embolism are discussed. Despite the comprehensive coverage of the guidelines for pulmonary embolism at previous conferences, discussions about controversies in the diagnosis and treatment of this condition in specific cases were debated and are addressed in the first section of this article. We then report on an interesting pro–con debate about the current classification of pulmonary hypertension. We further report on presentations on Group 3 pulmonary hypertension, with research exploring pathogenesis, phenotyping, diagnosis and treatment; important contributions on the diagnosis of post-capillary pulmonary hypertension are also included. Finally, we summarise the latest evidence presented on pulmonary vascular disease and COVID-19 and a statement on the new imaging guidelines for pulmonary vascular disease from the Fleischner Society.
UR - http://www.scopus.com/inward/record.url?scp=85131159961&partnerID=8YFLogxK
U2 - https://doi.org/10.1183/23120541.00665-2021
DO - https://doi.org/10.1183/23120541.00665-2021
M3 - Article
C2 - 35615412
SN - 2044-6055
VL - 8
JO - BMJ open
JF - BMJ open
IS - 2
M1 - 00665-2021
ER -